{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:08:49Z","timestamp":1779246529331,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metastasis-directed radiotherapy is of increasing importance in the multidisciplinary management of oligometastatic non-small cell lung cancer (NSCLC), but outcome patterns for stereotactic body radiotherapy (SBRT) of bone oligometastases (BoM) remain insufficiently defined. We aimed to determine oncological outcomes and prognostic factors of SBRT for BoM of NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Patients with NSCLC treated with SBRT for &lt;\u20095 BoM between 2010 and 2024 at 15 European cancer centers were retrospectively analyzed. Outcomes included freedom from local recurrence (FFLR), progression-free survival (PFS), overall survival (OS), and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With a median follow-up of 14 months (IQR: 7\u201324 months), 85 patients with 111 treated BoM were analyzed. The 2-year FFLR was 87.2% (95%-CI: 73.3%-94.1%). The 1-\/2-year PFS for singular BoM was 60.1% (CI: 44.6%-72.5%)\/ 39.9% (CI: 24.6%-54.8%), while for 2\u20133 BoM they amounted to 10.2% (95%-CI: 0.6%-35.8%) and 0%. In multivariable analysis, less favorable outcome for OS and PFS was associated with larger BoM (HR 1.003;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01 and HR 1.005,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and increased number of treated BoM (HR 1.72;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03 and HR 1.93;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Treatment was well tolerated, with fracture rates of 5.4% and no grade 4 and 5 adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multicenter cohort analysis revealed that SBRT of BoM from NSCLC appears to be an effective and well-tolerated treatment. Presence of singular BoM was a favorable prognostic factor. Prospective studies are needed to confirm these findings and to determine the role of SBRT in the multidisciplinary management of oligometastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02855-4","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:33:10Z","timestamp":1779197590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Sebastian","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabell","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"von Wachter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Sabrina","family":"Schunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Drabke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Klischies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Wittenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Willner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Lohaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"K\u00e4stner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Meents","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priska","family":"Bank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Slavik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Burkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Partl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg Andreas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Dzierma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Trommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"R\u00fchle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Moustakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Boda-Heggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"N\u00e4gler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2855_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2855_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020.","journal-title":"Lung Cancer"},{"key":"2855_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","volume":"7","author":"L Landi","year":"2019","unstructured":"Landi L, D\u2019Inc\u00e0 F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantedosi F, Calabro\u2019 L, Cappuzzo F. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019;7:316. https:\/\/doi.org\/10.1186\/s40425-019-0793-8.","journal-title":"J Immunother Cancer"},{"key":"2855_CR4","doi-asserted-by":"publisher","unstructured":"Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, de Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D\u2019Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal MG, Bello RA, Belderbos P, Bironzo S, Carnio S, Ricciardi A, Grieco A, de Toma C, Proto A, Friedlaender O, Cantale B, Ricciuti A, Addeo G, Metro C, Ficorella G, Porzio. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u2265\u200950%, Cancer Immunol Immunother. 2020;69:2209\u20132221. https:\/\/doi.org\/10.1007\/s00262-020-02613-9.","DOI":"10.1007\/s00262-020-02613-9"},{"key":"2855_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00432-022-04120-z","volume":"149","author":"A de Giglio","year":"2023","unstructured":"de Giglio A, Deiana C, Di Federico A. Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol. 2023;149:1835\u201347. https:\/\/doi.org\/10.1007\/s00432-022-04120-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2855_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10555-024-10236-0","volume":"44","author":"A Gueiderikh","year":"2025","unstructured":"Gueiderikh A, Faivre J-C, Golfier C, Escande A, Thureau S. Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art. Cancer Metastasis Rev. 2025;44:28. https:\/\/doi.org\/10.1007\/s10555-024-10236-0.","journal-title":"Cancer Metastasis Rev"},{"key":"2855_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.radonc.2015.10.015","volume":"118","author":"MS Tiwana","year":"2016","unstructured":"Tiwana MS, Barnes M, Yurkowski E, Roden K, Olson RA. Incidence and treatment patterns of complicated bone metastases in a population-based radiotherapy program. Radiother Oncol. 2016;118:552\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2015.10.015.","journal-title":"Radiother Oncol"},{"key":"2855_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden J, Willmann J, Spa\u0142ek M, Oldenburger E, Brown S, Kazmierska J, Andratschke N, Menten J, van der Linden Y, Hoskin P. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol. 2022;173:197\u2013206. https:\/\/doi.org\/10.1016\/j.radonc.2022.05.024.","journal-title":"Radiother Oncol"},{"key":"2855_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7:4\u201312. https:\/\/doi.org\/10.1016\/j.prro.2016.08.001.","journal-title":"Pract Radiat Oncol"},{"key":"2855_CR10","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"},{"key":"2855_CR11","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non\u2013Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. JCO. 2019;37:1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","journal-title":"JCO"},{"key":"2855_CR12","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Consolidative Radiotherapy for Limited Metastatic Non\u2013Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4:e173501\u2013173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","journal-title":"JAMA Oncol"},{"key":"2855_CR13","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar P, Hu C, Gomez DR, Timmerman RD, Simone CB, Robinson CG, Gerber DE, Waqar SN, Donington J, Swisher S, Weldon M, Wu J, Faller BA, Rashdan S, Stephans KL, Sampson P, Higgins KA, Nowak RK, Lyness J, Bradley JD. NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). JCO. 2024;42:8506. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8506.","journal-title":"JCO"},{"key":"2855_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"X-S Wang","year":"2023","unstructured":"Wang X-S, Bai Y-F, Verma V, Yu R-L, Tian W, Ao R, Deng Y, Zhu X-Q, Liu H, Pan H-X, Yang L, Bai H-S, Luo X, Guo Y, Zhou M-X, Sun Y-M, Zhang Z-C, Li S-M, Cheng X, Tan B-X, Han L-F, Liu Y-Y, Zhang K, Zeng F-X, Jia L, Hao X-B, Wang Y-Y, Feng G, Xie K, Lu Y, Zeng M. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023;115:742\u20138. https:\/\/doi.org\/10.1093\/jnci\/djac015.","journal-title":"J Natl Cancer Inst"},{"key":"2855_CR15","doi-asserted-by":"publisher","first-page":"e2355409","DOI":"10.1001\/jamanetworkopen.2023.55409","volume":"7","author":"BJJ Bindels","year":"2024","unstructured":"Bindels BJJ, Mercier C, Gal R, Verlaan J-J, Verhoeff JJC, Dirix P, Ost P, Kasperts N, van der Linden, Yvette M, Verkooijen HM, van der Velden, Joanne M. Stereotactic Body and Conventional Radiotherapy for Painful Bone Metastases: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7:e2355409. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.55409.","journal-title":"JAMA Netw Open"},{"key":"2855_CR16","doi-asserted-by":"publisher","first-page":"109966","DOI":"10.1016\/j.radonc.2023.109966","volume":"190","author":"M Guckenberger","year":"2024","unstructured":"Guckenberger M, Andratschke N, Belka C, Bellut D, Cuccia F, Dahele M, Guninski RS, Josipovic M, Mancosu P, Minniti G, Niyazi M, Ricardi U, Munck Af Rosenschold P, Sahgal A, Tsang Y, Verbakel W, Alongi F. ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases. Radiother Oncol. 2024;190:109966. https:\/\/doi.org\/10.1016\/j.radonc.2023.109966.","journal-title":"Radiother Oncol"},{"key":"2855_CR17","doi-asserted-by":"publisher","first-page":"100716","DOI":"10.1016\/j.ctro.2023.100716","volume":"45","author":"L Burgess","year":"2024","unstructured":"Burgess L, Nguyen E, Tseng C-L, Guckenberger M, Lo SS, Zhang B, Nielsen M, Maralani P, Nguyen Q-N, Sahgal A. Practice and principles of stereotactic body radiation therapy for spine and non-spine bone metastases. Clin Translational Radiation Oncol. 2024;45:100716. https:\/\/doi.org\/10.1016\/j.ctro.2023.100716.","journal-title":"Clin Translational Radiation Oncol"},{"key":"2855_CR18","doi-asserted-by":"publisher","first-page":"110717","DOI":"10.1016\/j.radonc.2025.110717","volume":"205","author":"TK Nguyen","year":"2025","unstructured":"Nguyen TK, Louie AV, Kotecha R, Saxena A, Zhang Y, Guckenberger M, Kim M-S, Scorsetti M, Slotman BJ, Lo SS, Sahgal A, Tree AC. Stereotactic body radiotherapy for non-spine bone metastases: A meta-analysis and international stereotactic radiosurgery society (ISRS) clinical practice guidelines. Radiother Oncol. 2025;205:110717. https:\/\/doi.org\/10.1016\/j.radonc.2025.110717.","journal-title":"Radiother Oncol"},{"key":"2855_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11912-024-01515-8","volume":"26","author":"AJ Grosinger","year":"2024","unstructured":"Grosinger AJ, Alcorn SR. An Update on the Management of Bone Metastases. Curr Oncol Rep. 2024;26:400\u20138. https:\/\/doi.org\/10.1007\/s11912-024-01515-8.","journal-title":"Curr Oncol Rep"},{"key":"2855_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","volume":"42","author":"EF Gillespie","year":"2024","unstructured":"Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, Barker CA, Kotecha R, McIntosh A, Vaynrub M, Bartelstein MK, Mitchell A, Guttmann DM, Yerramilli D, Higginson DS, Yamada YJ, Kohutek ZA, Powell SN, Tsai J, Yang JT. Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial. J Clin Oncol. 2024;42:38\u201346. https:\/\/doi.org\/10.1200\/JCO.23.00753.","journal-title":"J Clin Oncol"},{"key":"2855_CR21","doi-asserted-by":"publisher","unstructured":"Chmiel E, Guckenberger M, Gillespie EF, Siva S. Sharper focus, greater comfort? Lessons from the ROBOMET trial. JCO. 2025;JCO2500659. https:\/\/doi.org\/10.1200\/JCO-25-00659.","DOI":"10.1200\/JCO-25-00659"},{"key":"2855_CR22","doi-asserted-by":"publisher","unstructured":"Mercier C, Billiet C, Ost P, Vandecasteele K, de Kerf G, Claessens M, van Laere S, Vermeulen P, Dirix L, Lievens Y, Verellen D, Dirix P. Dose-escalated stereotactic versus conventional radiotherapy for painful bone metastases (ROBOMET): a multicenter, patient-blinded randomized clinical trial. JCO. 2025;JCO2401447. https:\/\/doi.org\/10.1200\/JCO-24-01447.","DOI":"10.1200\/JCO-24-01447"},{"key":"2855_CR23","doi-asserted-by":"publisher","first-page":"110235","DOI":"10.1016\/j.radonc.2024.110235","volume":"195","author":"SM Christ","year":"2024","unstructured":"Christ SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P, Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, Guckenberger M. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiother Oncol. 2024;195:110235. https:\/\/doi.org\/10.1016\/j.radonc.2024.110235.","journal-title":"Radiother Oncol"},{"key":"2855_CR24","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/s1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans A-MC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, M\u00e9ndez A, Romero U, Ricardi NS, Russell DH, Schanne M, Scorsetti B, Tombal D, Verellen C, Verfaillie P, Ost. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18\u201328. https:\/\/doi.org\/10.1016\/s1470-2045(19)30718-1.","journal-title":"Lancet Oncol"},{"key":"2855_CR25","doi-asserted-by":"crossref","unstructured":"Seuntjens J. ICRU Report 91: prescribing, recording, and reporting of stereotactic treatments with small photon beams. J ICRU. 2014;14.","DOI":"10.1093\/jicru_ndx017"},{"key":"2855_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","volume":"195","author":"L Wilke","year":"2019","unstructured":"Wilke L, Andratschke N, Blanck O, Brunner TB, Combs SE, Grosu A-L, Moustakis C, Schmitt D, Baus WW, Guckenberger M. ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. Strahlenther Onkol. 2019;195:193\u20138. https:\/\/doi.org\/10.1007\/s00066-018-1416-x.","journal-title":"Strahlenther Onkol"},{"key":"2855_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM van Leeuwen","year":"2018","unstructured":"van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, Kok HP. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13:96. https:\/\/doi.org\/10.1186\/s13014-018-1040-z.","journal-title":"Radiat Oncol"},{"key":"2855_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","volume":"196","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S, Moustakis C. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol. 2020;196:417\u201320. https:\/\/doi.org\/10.1007\/s00066-020-01603-1.","journal-title":"Strahlenther Onkol"},{"key":"2855_CR29","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 10 Apr 2025."},{"key":"2855_CR30","doi-asserted-by":"publisher","first-page":"111485","DOI":"10.1016\/j.radonc.2026.111485","volume":"219","author":"F N\u00e4gler","year":"2026","unstructured":"N\u00e4gler F, Sch\u00e4fer S, Seiler I, von Wachter C, Balermpas P, Loi M, Bonomo P, Slavik M, Burkon P, K\u00e4stner L, Meents J, Lohaus F, Willner J, Schunn AS, Drabke S, Klischies K, Wittenstein O, Bank P, Partl R, M\u00fcller JA, Gawish A, Gr\u00fcn A, Baehr A, Trommer M, Gkika E, Mader T, Holy R, Frerker B, Ehret F, R\u00fchle A, Guckenberger M, Moustakis C, Brunner TB, Blanck O, Boda-Heggemann J, Nicolay NH. Outcomes of stereotactic body radiotherapy for bone oligometastases in older patients\u2009\u2013\u2009A European multicenter cohort study. Radiother Oncol. 2026;219:111485. https:\/\/doi.org\/10.1016\/j.radonc.2026.111485.","journal-title":"Radiother Oncol"},{"key":"2855_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00066-020-01583-2","volume":"196","author":"D Schmitt","year":"2020","unstructured":"Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm M-L, Baus WW, Moustakis C. Technological quality requirements for stereotactic radiotherapy Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy. Strahlenther Onkol. 2020;196:421\u201343. https:\/\/doi.org\/10.1007\/s00066-020-01583-2.","journal-title":"Strahlenther Onkol"},{"key":"2855_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-025-02387-y","author":"F N\u00e4gler","year":"2025","unstructured":"N\u00e4gler F, Gleim N, Seiler I, R\u00fchle A, Hering K, Seidel C, Gkika E, Krug D, Blanck O, Moustakis C, Brunner TB, Wittig-Sauerwein A, Nicolay NH. Stereotactic radiotherapy for spinal and non-spinal bone metastases: a patterns-of-care analysis in German-speaking countries as part of a project of the interdisciplinary Radiosurgery and Stereotactic Radiotherapy Working Group of the DEGRO\/DGMP. Strahlenther Onkol. 2025. https:\/\/doi.org\/10.1007\/s00066-025-02387-y.","journal-title":"Strahlenther Onkol"},{"key":"2855_CR33","doi-asserted-by":"publisher","unstructured":"N\u00e4gler F, Seiler I, Sch\u00e4fer S, Meents J, Lohaus F, Gr\u00fcn A, Wittenstein O, Klischies K, Remmele J, R\u00fchle A, Eckl M, Blanck O, Boda-Heggemann J, Giordano FA, Moustakis C, Nicolay NH, K\u00e4stner L. Stereotactic body radiotherapy for spine and non-spine bone metastases in prostate carcinoma \u2013 a multicenter cohort analysis. J Bone Oncol. 2025;100710. https:\/\/doi.org\/10.1016\/j.jbo.2025.100710.","DOI":"10.1016\/j.jbo.2025.100710"},{"key":"2855_CR34","doi-asserted-by":"publisher","first-page":"111276","DOI":"10.1016\/j.radonc.2025.111276","volume":"214","author":"I Seiler","year":"2026","unstructured":"Seiler I, Sch\u00e4fer S, von Wachter C, Balermpas P, Slavik M, Burkon P, Meents J, K\u00e4stner L, Lohaus F, Willner J, Schunn AS, Drabke S, Klischies K, Wittenstein O, Bank P, Partl R, M\u00fcller J-A, Gawish A, Gr\u00fcn A, Baehr A, Trommer M, Glasmacher A, Mader T, Holy R, Dzierma Y, Ehret F, R\u00fchle A, Guckenberger M, Moustakis C, Brunner T, Blanck O, Boda-Heggemann J, Nicolay NH, N\u00e4gler F. Impact of target volume and dose concepts on the outcomes of prostate cancer patients treated with stereotactic body radiotherapy for spinal metastases\u2009\u2013\u2009a European multicenter cohort study. Radiother Oncol. 2026;214:111276. https:\/\/doi.org\/10.1016\/j.radonc.2025.111276.","journal-title":"Radiother Oncol"},{"key":"2855_CR35","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","volume":"83","author":"BW Cox","year":"2012","unstructured":"Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83:e597\u2013605. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.009.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2855_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","volume":"15","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O, Kenai H, Moriki A, Suzuki S, Kida Y, Iwai Y, Hayashi M, Onishi H, Gondo M, Sato M, Akimitsu T, Kubo K, Kikuchi Y, Shibasaki T, Goto T, Takanashi M, Mori Y, Takakura K, Saeki N, Kunieda E, Aoyama H, Momoshima S, Tsuchiya K. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15:387\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(14)70061-0.","journal-title":"Lancet Oncol"},{"key":"2855_CR37","doi-asserted-by":"publisher","first-page":"S1729","DOI":"10.1016\/j.annonc.2025.09.086","volume":"36","author":"YY Elamin","year":"2025","unstructured":"Elamin YY, Gandhi S, Antonoff M, Gibbons D, Negrao MV, Cascone T, Gay CM, Byers LA, Blumenschein G, Rusthoven CG, Vaporciyan A, Blakely CM, Gomez D, Feng L, Zhang J, Altan M, Le X, Chang JY, Swisher S, Heymach J. LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2025;36:S1729. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.086.","journal-title":"Ann Oncol"},{"key":"2855_CR38","doi-asserted-by":"publisher","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023;184:109681. https:\/\/doi.org\/10.1016\/j.radonc.2023.109681.","journal-title":"Radiother Oncol"},{"key":"2855_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block CURB oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403:171\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3.","journal-title":"Lancet"},{"key":"2855_CR40","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1111\/1759-7714.13597","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Wang L, Chen S, Zhou F, Zhao J, Zhao W, Su C. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer. 2020;11:2812\u20139. https:\/\/doi.org\/10.1111\/1759-7714.13597.","journal-title":"Thorac Cancer"},{"key":"2855_CR41","doi-asserted-by":"publisher","unstructured":"Bianchi D, Falcinelli C, Molinari L, Gizzi A, Di Martino A. Osteolytic vs. osteoblastic metastatic lesion: computational modeling of the mechanical behavior in the human vertebra after screws fixation procedure. J Clin Med. 2022;11. https:\/\/doi.org\/10.3390\/jcm11102850.","DOI":"10.3390\/jcm11102850"},{"key":"2855_CR42","doi-asserted-by":"publisher","first-page":"109969","DOI":"10.1016\/j.radonc.2023.109969","volume":"190","author":"RS Guninski","year":"2024","unstructured":"Guninski RS, Cuccia F, Alongi F, Andratschke N, Belka C, Bellut D, Dahele M, Josipovic M, Kroese TE, Mancosu P, Minniti G, Niyazi M, Ricardi U, Munck Af Rosenschold P, Sahgal A, Tsang Y, Verbakel WFAR, Guckenberger M. Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline. Radiother Oncol. 2024;190:109969. https:\/\/doi.org\/10.1016\/j.radonc.2023.109969.","journal-title":"Radiother Oncol"},{"key":"2855_CR43","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ijrobp.2024.11.082","volume":"121","author":"AW Chan","year":"2025","unstructured":"Chan AW, Zeng KL, Moore-Palhares D, Atenafu EG, Chen H, Myrehaug S, Ruschin M, Soliman H, Tseng C-L, Zhang B-B, Whyne C, Maralani P, Sahgal A, Detsky J. Spine Stereotactic Body Radiation Therapy in Geriatric Patients: Implications of Age and Dose on Iatrogenic Vertebral Compression Fracture Risk. Int J Radiat Oncol Biol Phys. 2025;121:1185\u201393. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.082.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02855-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:47:22Z","timestamp":1779245242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02855-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2855"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02855-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the ethical principles of the Declaration of Helsinki. This study has been approved by the leading Ethics Committee (127\/24-ek) as well as by all local Ethics Committees of the participating centers. Informed consent to participate in the study was not required. All methods used in this study were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Panagiotis Balermpas reports a relationship with ViewRay Systems Inc, Siemens Healthineers that includes: funding grants. Panagiotis Balermpas reports a relationship with MSD, Siemens Healthineers, Merck that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Olaf Wittenstein reports a relationship with Brainlab AG that includes: consulting or advisory. Olaf Wittenstein reports a relationship with Novocure that includes: speaking and lecture fees. Fabian Lohaus reports a relationship with Regeneron Germany inc. that includes: speaking and lecture fees. Lena Kaestner reports a relationship with AstraZeneca that includes: speaking and lecture fees. Alexander Ruehle reports a relationship with Novocure that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Alexander Ruehle reports a relationship with Johnson & Johnson, Need Inc. that includes: consulting or advisory. Alexander Ruehle reports a relationship with AstraZeneca that includes: speaking and lecture fees. Alexander Ruehle reports a relationship with HNCIG that includes: board membership. Matthias Guckenberger reports a relationship with AstraZeneca that includes: speaking and lecture fees. Matthias Guckenberger reports a relationship with Siemens Healthineers\/Varian, AstraZeneca, Johnson&Johnson that includes: consulting or advisory. Matthias Guckenberger reports a relationship with Siemens Healthineers\/Varian, AstraZeneca that includes: funding grants. Matthias Guckenberger reports a relationship with ESTRO that includes: board membership\/ ESTRO president. Thomas Brunner reports a relationship with Varian Medical Systems Inc, Elekta, BrainLab, AstraZeneca, VisionRT, Novocure that includes: speaking and lecture fees. Thomas Brunner reports a relationship with Onconovum that includes: travel reimbursement. Oliver Blanck reports a relationship with DEGRO, DGMP that includes: board membership. Judit Boda-Heggemann reports a relationship with EBAMed that includes: consulting or advisory. Judit Boda-Heggemann reports a relationship with AstraZeneca, Bristol Myers Squibb that includes: speaking and lecture fees. Nils H. Nicolay reports a relationship with Novocure Inc that includes: funding grants. Nils H. Nicolay reports a relationship with Novocure, AstraZeneca, Sun Pharmaceuticals that includes: speaking and lecture fees. Nils H. Nicolay reports a relationship with Merck that includes: travel reimbursement. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}